Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial

Basit Öğe Kaydı
dc.contributor.authorSaip, P.
dc.contributor.authorEralp, Y.
dc.contributor.authorSen, F.
dc.contributor.authorKaraca, H.
dc.contributor.authorOzkan, M.
dc.contributor.authorCetin, B.
dc.contributor.authorBenekli, M.
dc.date.accessioned2024-04-24T16:10:57Z
dc.date.available2024-04-24T16:10:57Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: The aim of this explorative phase II study was to evaluate the activity and safety of lapatinib in combination with intravenous vinorelbine in women with HER2 positive metastatic or recurrent breast cancer. Methods: Twenty-nine patients were enrolled. The primary objectives were response and clinical benefit (CB) rates, secondary objectives were toxicity, response duration and progression free survival. Patients received 1250 mg oral lapatinib continuously once daily and intravenous vinorelbine 20-25 mg/m(2) on days 1 and 8, every 3 weeks. Results: Although 25 patients were evaluable for response, according to intend to treat analysis of 28 patients; 14% had confirmed partial response (PR) and 36% had stable disease more than 24 weeks with a CB rate of 50%. Sixty four percent of the patients suffered from grade 3-4 hematologic and 18% from grade 3 extra-hematologic toxicities. Conclusion: The results of this trial provide evidence to further investigate the potential of this combination for patients unsuitable for trastuzumab or who become refractory to trastuzumab. (C) 2013 Elsevier Ltd. All rights reserved.en_US
dc.description.sponsorshipGlaxoSmithKlineen_US
dc.description.sponsorshipThis is an investigator initiated and GlaxoSmithKline supported study.en_US
dc.identifier.doi10.1016/j.breast.2013.07.048
dc.identifier.endpage633en_US
dc.identifier.issn0960-9776
dc.identifier.issn1532-3080
dc.identifier.issue5en_US
dc.identifier.pmid23954396
dc.identifier.scopus2-s2.0-84884131003
dc.identifier.scopusqualityQ1
dc.identifier.startpage628en_US
dc.identifier.urihttps://doi.org/10.1016/j.breast.2013.07.048
dc.identifier.urihttps://hdl.handle.net/11468/15202
dc.identifier.volume22en_US
dc.identifier.wosWOS:000324516800008
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherChurchill Livingstoneen_US
dc.relation.ispartofBreast
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHer2 Positiveen_US
dc.subjectLapatiniben_US
dc.subjectMetastatic Breast Canceren_US
dc.subjectVinorelbineen_US
dc.titlePhase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trialen_US
dc.titlePhase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu